AMNEAL PHARMACEUTICALS, INC. Cost of Revenue
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Cost of Revenue of $461.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $461.69M, a 5.35% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $402.41M, a 8.45% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $517.13M, a 10.58% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $510.54M, a 17.93% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $1.91B, a 7.44% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $1.77B, a 12.74% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $1.57B, a 10.19% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $1.43B, a 7.77% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $461.69M 10-Q · filed 2026-08-06 | $864.10M 10-Q · filed 2026-08-06 | $1.38B derived: sum of 3 quarters · filed 2026-08-06 | $1.89B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $402.41M 10-Q · filed 2026-05-07 | $919.53M derived: sum of 2 quarters · filed 2026-05-07 | $1.43B derived: sum of 3 quarters · filed 2026-05-07 | $1.87B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $517.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.03B derived: sum of 2 quarters · filed 2026-02-27 | $1.47B derived: sum of 3 quarters · filed 2026-08-06 | $1.91B 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $510.54M 10-Q · filed 2025-11-06 | $948.79M derived: sum of 2 quarters · filed 2026-08-06 | $1.39B 10-Q · filed 2025-11-06 | $1.86B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $438.25M 10-Q · filed 2026-08-06 | $877.78M 10-Q · filed 2026-08-06 | $1.35B derived: sum of 3 quarters · filed 2026-08-06 | $1.78B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $439.53M 10-Q · filed 2026-05-07 | $907.17M derived: sum of 2 quarters · filed 2026-05-07 | $1.34B derived: sum of 3 quarters · filed 2026-05-07 | $1.79B derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $467.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $900.55M derived: sum of 2 quarters · filed 2026-02-27 | $1.35B derived: sum of 3 quarters · filed 2026-02-27 | $1.77B 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $432.91M 10-Q · filed 2025-11-06 | $884.74M derived: sum of 2 quarters · filed 2025-11-06 | $1.31B 10-Q · filed 2025-11-06 | $1.73B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $451.83M 10-Q · filed 2025-08-07 | $872.96M 10-Q · filed 2025-08-07 | $1.30B derived: sum of 3 quarters · filed 2026-02-27 | $1.69B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $421.13M 10-Q · filed 2025-05-07 | $848.28M derived: sum of 2 quarters · filed 2026-02-27 | $1.24B derived: sum of 3 quarters · filed 2026-02-27 | $1.61B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $427.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $814.66M derived: sum of 2 quarters · filed 2026-02-27 | $1.19B derived: sum of 3 quarters · filed 2026-02-27 | $1.57B 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $387.51M 10-Q · filed 2024-11-12 | $766.53M derived: sum of 2 quarters · filed 2024-11-12 | $1.15B 10-Q · filed 2024-11-12 | $1.54B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $379.02M 10-Q · filed 2024-08-09 | $758.38M 10-Q · filed 2024-08-09 | $1.15B derived: sum of 3 quarters · filed 2025-02-28 | $1.50B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $379.35M 10-Q · filed 2024-05-08 | $773.73M derived: sum of 2 quarters · filed 2025-02-28 | $1.13B derived: sum of 3 quarters · filed 2025-02-28 | $1.48B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $394.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $745.70M derived: sum of 2 quarters · filed 2025-02-28 | $1.10B derived: sum of 3 quarters · filed 2025-02-28 | $1.43B 10-K · filed 2025-02-28 | $1.42B 10-K · filed 2023-03-03 | |||
| 2022-09-30 | $351.33M 10-Q · filed 2023-11-09 | $350.65M 10-Q · filed 2022-11-07 | $710.16M derived: sum of 2 quarters · filed 2023-11-09 | $1.03B 10-Q · filed 2023-11-09 | $1.03B 10-Q · filed 2022-11-07 | $1.40B derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $358.84M 10-Q · filed 2023-08-08 | $353.72M 10-Q · filed 2022-08-08 | $681.90M 10-Q · filed 2023-08-08 | $676.79M 10-Q · filed 2022-08-08 | $1.05B derived: sum of 3 quarters · filed 2024-03-14 | $1.38B derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $323.06M 10-Q · filed 2023-05-09 | $694.24M derived: sum of 2 quarters · filed 2024-03-14 | $1.02B derived: sum of 3 quarters · filed 2024-03-14 | $1.35B derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $371.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $700.58M derived: sum of 2 quarters · filed 2024-03-14 | $1.02B derived: sum of 3 quarters · filed 2024-03-14 | $1.32B 10-K · filed 2024-03-14 | $1.30B 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $329.39M 10-Q · filed 2022-11-07 | $651.97M derived: sum of 2 quarters · filed 2022-11-07 | $953.51M 10-Q · filed 2022-11-07 | $1.30B derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $322.58M 10-Q · filed 2022-08-08 | $624.12M 10-Q · filed 2022-08-08 | $967.08M derived: sum of 3 quarters · filed 2023-03-03 | $1.32B derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $301.54M 10-Q · filed 2022-05-06 | $644.50M derived: sum of 2 quarters · filed 2023-03-03 | $997.85M derived: sum of 3 quarters · filed 2023-03-03 | $1.32B derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $342.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $696.31M derived: sum of 2 quarters · filed 2023-03-03 | $1.02B derived: sum of 3 quarters · filed 2023-03-03 | $1.33B 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $353.35M 10-Q · filed 2021-11-08 | $673.01M derived: sum of 2 quarters · filed 2021-11-08 | $986.59M 10-Q · filed 2021-11-08 | $1.26B derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $319.67M 10-Q · filed 2021-08-09 | $633.24M 10-Q · filed 2021-08-09 | $906.62M derived: sum of 3 quarters · filed 2022-03-01 | $1.17B derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $313.58M 10-Q · filed 2021-05-07 | $586.95M derived: sum of 2 quarters · filed 2022-03-01 | $854.67M derived: sum of 3 quarters · filed 2022-03-01 | $1.15B derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $273.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $541.09M derived: sum of 2 quarters · filed 2022-03-01 | $837.47M derived: sum of 3 quarters · filed 2022-03-01 | $1.15B 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $267.72M 10-Q · filed 2020-11-06 | $564.10M derived: sum of 2 quarters · filed 2020-11-06 | $873.84M 10-Q · filed 2020-11-06 | $1.18B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $296.38M 10-Q · filed 2020-08-06 | $606.12M 10-Q · filed 2020-08-06 | $910.24M derived: sum of 3 quarters · filed 2021-03-01 | $1.18B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $309.74M 10-Q · filed 2020-05-11 | $613.86M derived: sum of 2 quarters · filed 2021-03-01 | $882.43M derived: sum of 3 quarters · filed 2021-03-01 | $1.12B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $304.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $572.69M derived: sum of 2 quarters · filed 2021-03-01 | $808.18M derived: sum of 3 quarters · filed 2021-03-01 | $938.77M 10-K · filed 2021-03-01 | $946.59M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $268.57M 10-Q · filed 2019-11-07 | $276.38M 10-Q · filed 2018-11-07 | $504.06M derived: sum of 2 quarters · filed 2019-11-07 | $634.65M 10-Q · filed 2019-11-07 | $642.47M 10-Q · filed 2018-11-07 | $776.61M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $235.49M 10-Q · filed 2019-08-05 | $366.09M 10-Q · filed 2019-08-05 | $508.04M derived: sum of 3 quarters · filed 2020-03-02 | $627.76M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $130.59M 10-Q · filed 2019-05-09 | $272.55M derived: sum of 2 quarters · filed 2020-03-02 | $392.27M derived: sum of 3 quarters · filed 2020-03-02 | $528.40M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $141.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $261.67M derived: sum of 2 quarters · filed 2020-03-02 | $397.81M derived: sum of 3 quarters · filed 2020-03-02 | $507.48M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $119.72M 10-Q · filed 2018-11-07 | $255.86M derived: sum of 2 quarters · filed 2018-11-07 | $365.52M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $136.14M 10-Q · filed 2018-08-09 | $245.80M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $420.77M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |